Current research has identified several factors associated with poor prognosis in PTL patients: the presence of B symptoms, specific genetic alterations such as BTG2 mutation (54), TP53 mutation, HLA deletion, a serum LDH to CSF LDH ratio of6.5 or higher (55), loss of 5-hydroxymethylcytosine (56), low T lymphocyte content or low expression of T lymphocyte characteristic genes in TME, and p53 immunohistochemical overexpression (defined as positive immunohistochemical staining of at least 50% of tumor cells in testicular tissue (57)). The gene discussed is TP53; the disease is neoplasm.